GlaxoSmithKline PLC announces change to the Board of Directors
Issued – 28 September 2007, London
GlaxoSmithKline plc (GSK) announces that Professor Sir Roy Anderson has been appointed a Non-Executive Director and will join the Board of the Company with effect from 1 October 2007.
Professor Anderson is Professor of Infectious Disease Epidemiology, ImperialCollege, Londonand, until 30 September 2007, Chief Scientific Advisor to the UK’s Ministry of Defence.
In commenting on his appointment, Sir Christopher Gent, Chairman of GSK, said, “I am delighted that Professor Anderson has agreed to join the Board. In addition to fulfilling the usual responsibilities of a Non-Executive Director, he will spend time within our research and development organisation and, with his experience, will provide the Board with valuable insights to scientific developments outside GSK.”
Professor Anderson’s biographical details are given below together with a table showing the membership of the Board with effect from 1 October 2007.
Simon Bicknell
Company Secretary
28 September 2007
Notes
The Board has determined that Professor Anderson is independent in accordance with the Combined Code on Corporate Governance.
Biographical details
Professor Sir Roy Anderson
Age 60. Professor Anderson is the Professor of Infectious Disease Epidemiology in the Faculty of Medicine, ImperialCollege, Londonand, until 30 September 2007, the Chief Scientific Adviser at the Ministry of Defence in the United Kingdom. It was announced on 21 June 2007 that Professor Anderson will succeed Sir Richard Sykes as Rector of Imperial College in the summer of 2008.
He is a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences, a Fellow of the Royal Statistical Society, Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences.
He has published over 450 scientific papers on the epidemiology, population biology, evolution and control of a wide variety of infectious disease agents, including HIV, BSE, vCJD, parasitic helminths and protozoa, and respiratory tract viral and bacterial infections.
His principal research interests are epidemiology, biomathematics, demography, parasitology, immunology and health economics. He also has a keen interest in science policy and the public understanding of science.
He received a Knighthood in the Queen’s Birthday Honours in June 2006.
Board Membership with effect from 1 October 2007
Sir Christopher Gent, Chairman
Sir Ian Prosser, Senior Independent Non-Executive Director
Dr J-P Garnier, Chief Executive Officer
Mr J S Heslop, Chief Financial Officer
Dr Moncef Slaoui, Executive Director, Chairman, Research & Development
Professor Sir Roy Anderson, Independent Non-Executive Director
Dr Stephanie Burns, Independent Non-Executive Director
Mr H Lawrence Culp, Independent Non-Executive Director
Sir Crispin Davis, Independent Non-Executive Director
Sir Deryck Maughan, Independent Non-Executive Director
Dr Daniel Podolsky, Independent Non-Executive Director
Dr Ronaldo Schmitz, Independent Non-Executive Director
Mr Tom De Swaan, Independent Non Executive Director
Sir Robert Wilson, Independent Non-Executive Director
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Enquiries:
UK Media enquiries:
Philip Thomson
(020) 8047 5502
Alice Hunt
(020) 8047 5502
Joss Mathieson
(020) 8047 5502
Claire Brough
(020) 8047 5502
US Media enquiries:
Nancy Pekarek
(215) 751 7709
Mary Anne Rhyne
(919) 483 2839
European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
Sally Ferguson
(020) 8047 5543
US Analyst/ Investor enquiries:
Frank Murdolo
(215) 751 7002
Tom Curry
(215) 751 5419
